ATE483459T1 - Behandlung von überaktivität glatter muskulatur mit (r)-oxybutynin und (r)-desethyloxybutynin - Google Patents

Behandlung von überaktivität glatter muskulatur mit (r)-oxybutynin und (r)-desethyloxybutynin

Info

Publication number
ATE483459T1
ATE483459T1 AT00941235T AT00941235T ATE483459T1 AT E483459 T1 ATE483459 T1 AT E483459T1 AT 00941235 T AT00941235 T AT 00941235T AT 00941235 T AT00941235 T AT 00941235T AT E483459 T1 ATE483459 T1 AT E483459T1
Authority
AT
Austria
Prior art keywords
oxybutynin
smooth muscle
desethyloxybutynin
treating
optically pure
Prior art date
Application number
AT00941235T
Other languages
English (en)
Inventor
A Aberg
Original Assignee
Watson Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Watson Pharmaceuticals Inc filed Critical Watson Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE483459T1 publication Critical patent/ATE483459T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AT00941235T 2000-06-07 2000-06-07 Behandlung von überaktivität glatter muskulatur mit (r)-oxybutynin und (r)-desethyloxybutynin ATE483459T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/015515 WO2001093683A1 (en) 2000-06-07 2000-06-07 Treating smooth muscle hyperactivity with (r)-oxybutynin and (r)- desethyloxybutynin

Publications (1)

Publication Number Publication Date
ATE483459T1 true ATE483459T1 (de) 2010-10-15

Family

ID=21741461

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00941235T ATE483459T1 (de) 2000-06-07 2000-06-07 Behandlung von überaktivität glatter muskulatur mit (r)-oxybutynin und (r)-desethyloxybutynin

Country Status (9)

Country Link
EP (1) EP1286591B1 (de)
JP (1) JP5684964B2 (de)
CN (3) CN1454054A (de)
AT (1) ATE483459T1 (de)
AU (2) AU5596600A (de)
CA (1) CA2378754A1 (de)
DE (1) DE60045082D1 (de)
ES (1) ES2350330T3 (de)
WO (1) WO2001093683A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002241721A1 (en) * 2001-12-21 2003-09-02 Bridge Pharma, Inc. A non-arrhythmogenic metabolite of oxybutynin
EP1424079A1 (de) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Kombination eines beta-3-Rezeptoragonisten und eines Serotonin und/oder Norepinephrin-Wiederaufnahmeinhibitors
ATE361101T1 (de) * 2004-08-24 2007-05-15 Nutricia Nv Nahrungszusammensetzung die unverdauliche oligosaccharide enthält
US8920392B2 (en) 2009-05-05 2014-12-30 Watson Laboratories, Inc. Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
JP6253991B2 (ja) 2011-03-02 2017-12-27 ジェローム シェンターク， 肝臓脂肪症単独又はｃ型肝炎ウイルス感染を伴った肝臓脂肪症の治療のための組成物、治療法及び診断法
US10449193B2 (en) 2011-06-03 2019-10-22 Signpath Pharma Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies
US10238602B2 (en) 2011-06-03 2019-03-26 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies
US10117881B2 (en) 2011-06-03 2018-11-06 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies
US12004868B2 (en) 2011-06-03 2024-06-11 Signpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel
EP2714011B1 (de) 2011-06-03 2018-01-31 Signpath Pharma Inc. Liposomale abschwächung des arzneimittelinduzierten long-qt-syndroms mittels strom aus einem durch kalium verzögerten umrichter
US10349884B2 (en) 2011-06-03 2019-07-16 Sighpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
US20140135392A1 (en) * 2012-11-13 2014-05-15 NeuRx Pharmaceuticals LLC Methods for the treatment of sialorrhea
US20160151321A1 (en) 2012-11-13 2016-06-02 Dinesh C. Patel Methods for the treatment of sialorrhea
CN103169660B (zh) * 2013-04-15 2015-04-08 石正国 一种制备高包封率的利巴韦林脂质体口服乳
JP6895252B2 (ja) * 2013-12-18 2021-06-30 サインパス ファルマ, インク.Signpath Pharma, Inc. 心筋ｉｋｒチャネルの薬剤誘発性阻害のリポソームによる軽減
JP2017516813A (ja) 2014-06-03 2017-06-22 サインパス ファルマ, インク.Signpath Pharma, Inc. チャネル病を引き起こす薬物に対するｄｍｐｃ、ｄｍｐｇ、ｄｍｐｃ／ｄｍｐｇ、ｅｇｐｇ、ｌｙｓｏｐｇ及びｌｙｓｏｐｃの防御効果
KR102181659B1 (ko) 2016-04-27 2020-11-24 사인패스 파마 인코포레이티드 약물 유발된 방실 차단의 방지
JP2023531568A (ja) * 2020-07-03 2023-07-24 フォックスバイオ リミテッド ウィルス感染の低減

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4008269A (en) * 1970-05-05 1977-02-15 William H. Rorer, Inc. Phenylacetic acids
IT1231237B (it) * 1987-09-21 1991-11-26 Angeli Inst Spa Derivati eterociclici
US5677346A (en) * 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
US5973182A (en) * 1998-10-22 1999-10-26 Sepracor Inc. Carbonate Intermediates useful in the preparation of optically active cyclohexylphenylglycolate esters

Also Published As

Publication number Publication date
AU2000255966A1 (en) 2002-03-07
CN1451388A (zh) 2003-10-29
AU2000255966B2 (en) 2005-03-24
CN1454054A (zh) 2003-11-05
EP1286591A1 (de) 2003-03-05
JP2003535110A (ja) 2003-11-25
EP1286591B1 (de) 2010-10-06
ES2350330T3 (es) 2011-01-21
AU5596600A (en) 2001-12-17
CA2378754A1 (en) 2001-12-13
DE60045082D1 (de) 2010-11-18
EP1286591A4 (de) 2007-04-04
WO2001093683A1 (en) 2001-12-13
CN101108176A (zh) 2008-01-23
JP5684964B2 (ja) 2015-03-18

Similar Documents

Publication Publication Date Title
ATE483459T1 (de) Behandlung von überaktivität glatter muskulatur mit (r)-oxybutynin und (r)-desethyloxybutynin
CA2451474A1 (en) Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (mtp) and/or apolipoprotein b (apo b) secretion
DE60035232D1 (de) (S,S)-Reboxetine zur Behandlung von chronischen Erschöpfungssyndrom
MXPA03000809A (es) Polimero de polisiloxano, procedimiento para su preparacion y su uso.
NO20054296D0 (no) Anvendelse av palonosetron for behandling av kvalme og oppkast etter kirurgisk inngrep
DE60027769D1 (de) Pyrrolidin-derivate als inhibitoren von cyclischer amp-phosphodiesterase
MX2007002470A (es) Fenilaminotiazoles sustituidos y su uso.
EP1311272A4 (de) Neue methoden unter verwendung von cholinesteraseinhibitoren
NO20053045L (no) Kinolyl-pyrrol-pyrazoler.
NO20043038L (no) Polymorfe former av klopidogrel-hydrogensulfat
EP1862457A3 (de) Fluoropyrrolidine als Dipeptidylpeptidasehemmer
AU2002366641A1 (en) Methods for inhibiting ocular processes
BR122018009866B8 (pt) métodos para preparar compostos de éter aminocicloexílico e compostos intermediários
ATE197762T1 (de) Verwendung von optisch reines (+) norcisapride zur behandlung von erbrechen und zns-störungen
SE0104331D0 (sv) Novel compounds
DE60127131D1 (de) Tricyclische imidazopyridine
DE60025639D1 (de) Substituierte diazepan
NL1021504A1 (nl) Waterstofbehandelingsproces.
NO976112L (no) 1,6-disubstituerte isokromaner for behandling av migrene
CY1106409T1 (el) Παραγωγα κινολινης
WO2004098599A3 (en) Proton pump inhibitors for the treatment of lower abdominal disorders
WO2003092611A3 (en) Methods of inducing formation of functional and organized lymphatic vessels
ATE278722T1 (de) Organische polymere
MXPA03004450A (es) Compuestos triciclicos y sus usos.
NO20042138L (no) Forbindelser og fremgangsmate for behandling av hyperaktiv blaere

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties